Autologous Cell Therapy After Stroke

• Status: Withdrawn
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will examine the safety of two different cellular therapies in the treatment of stroke.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, Irvine
• Collaborator: University of California, San Diego

Criteria

Inclusion Criteria:

• Ischemic stroke that is supratentorial in location and < 72 hours old between stroke onset and bone marrow aspiration

• No major pre-stroke disability

• NIH stroke scale score of 7-24

• Able to undergo bedside bone marrow aspiration

• Age 18-85 years, inclusive

• Reasonable likelihood of receiving standard physical, occupational and speech rehabilitation therapy

Exclusion Criteria:

• No major active hematological, immunological, or oncological diagnoses

• Pregnancy

• Lactating mothers

• At least 24 hours time of any thrombolytic therapy and time of bone marrow aspiration

• Allergy to penicillin or to fetal bovine serum

• Active, major co-existent neurological or psychiatric disease

• Infection with HIV, hepatitis B or C, or syphilis

• Any diagnosis that makes survival to 90 days post-stroke unlikely

• Participation in an experimental therapeutic clinical trial in the prior three months